How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,192 results for

Mycobacterium Avium Complex

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1041. Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

1999 Clinical Trials

1042. Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia. Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

1999 Clinical Trials

1043. A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC) A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00002170 Recruitment Status : Completed First Posted : August 31, 2001 Last Update Posted : June 24, 2005 Sponsor: Agouron Pharmaceuticals Information

1999 Clinical Trials

1044. Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

1999 Clinical Trials

1045. A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

1999 Clinical Trials

1046. A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record (...) managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients The safety and scientific

1999 Clinical Trials

1047. A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00002058 Recruitment Status : Completed First

1999 Clinical Trials

1048. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. (Full text)

Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Levofloxacin, ofloxacin, and Bay Y 3118 are new fluoroquinolones with variable in vitro bacteriostatic and bactericidal activities against the Mycobacterium avium complex (MAC). The potential therapeutic activities of these agents both alone and combined with ethambutol were evaluated in a human macrophage test

1996 Antimicrobial Agents and Chemotherapy PubMed abstract

1049. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. (Full text)

Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. Macrolide resistance in Mycobacterium avium can be detected with an adaption of a commercially available RNA/RNA duplex mismatch assay (Ambion, Austin, Tex.). The sensitivity and specificity values for the assay were 100% when evaluated against 41 macrolide-resistant and -susceptible strains of M. avium. Resistant subpopulations of approximately 20% could be readily detected. The assay is simple

1996 Antimicrobial Agents and Chemotherapy PubMed abstract

1050. Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. (Full text)

Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. 8976833 1997 01 14 2018 11 13 0266-4348 72 4 1996 Aug Genitourinary medicine Genitourin Med Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. 272-6 Stephenson J M JM Department of Sexually Transmitted Diseases, University College, London Medical School, UK. Williams (...) I G IG eng Journal Article Review England Genitourin Med 8503853 0266-4348 0 Anti-Bacterial Agents 1W306TDA6S Rifabutin IM X Genitourin Med 1996 Oct;72(5):388 AIDS-Related Opportunistic Infections prevention & control Anti-Bacterial Agents adverse effects therapeutic use Antibiotic Prophylaxis Data Interpretation, Statistical Double-Blind Method Humans Mycobacterium avium-intracellulare Infection prevention & control Randomized Controlled Trials as Topic Research Design Rifabutin adverse effects

1996 Genitourinary Medicine PubMed abstract

1051. Susceptibility testing of Mycobacterium avium complex isolates. (Full text)

Susceptibility testing of Mycobacterium avium complex isolates. 8843278 1997 01 16 2018 11 13 0066-4804 40 8 1996 Aug Antimicrobial agents and chemotherapy Antimicrob. Agents Chemother. Susceptibility testing of Mycobacterium avium complex isolates. 1759-67 Heifets L L National Jewish Center for Immunology, and Respiratory Medicine, Denver, Colorado 80206, USA. eng Journal Article Review United States Antimicrob Agents Chemother 0315061 0066-4804 0 Anti-Bacterial Agents H1250JIK0A (...) Clarithromycin IM Anti-Bacterial Agents pharmacology therapeutic use Clarithromycin pharmacology therapeutic use Controlled Clinical Trials as Topic Drug Resistance, Microbial Humans Microbial Sensitivity Tests Mycobacterium avium Complex drug effects isolation & purification Mycobacterium avium-intracellulare Infection drug therapy microbiology 117 1996 8 1 1996 8 1 0 1 1996 8 1 0 0 ppublish 8843278 PMC163414 Antimicrob Agents Chemother. 1989 Aug;33(8):1298-301 2478073 Am Rev Respir Dis. 1990 Mar;141(3):626

1996 Antimicrobial Agents and Chemotherapy PubMed abstract

1052. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. (Full text)

Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Disseminated infections caused by the Mycobacterium avium-M. intracellulare complex (MAC) are the most frequent opportunistic bacterial infections in patients with AIDS. MAC isolates are resistant to many of the standard antituberculous drugs. Failure to obtain significant activities

1996 Antimicrobial Agents and Chemotherapy PubMed abstract

1053. Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex. (Full text)

Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex. The in vitro activities of pyrimethamine and dapsone alone and in combination were evaluated against 23 clinical isolates of Mycobacterium avium complex. The broth dilution MICs of dapsone and pyrimethamine alone ranged from 16 to > 64 micrograms/ml. Pyrimethamine in combination with a fixed concentration of dapsone at 0.5 microgram/ml showed enhanced activity, with an MIC range of 0.5

1996 Antimicrobial Agents and Chemotherapy PubMed abstract

1054. The role of tumour necrosis factor-alpha in combination with interferon-gamma or interleukin-1 in the induction of immunosuppressive macrophages because of Mycobacterium avium complex infection. (Full text)

The role of tumour necrosis factor-alpha in combination with interferon-gamma or interleukin-1 in the induction of immunosuppressive macrophages because of Mycobacterium avium complex infection. The role of some cytokines including tumour necrosis factor-alpha (TNF-alpha), interleukin-1 alpha (IL-1 alpha), interferon-gamma (IFN-gamma), transforming growth factor-beta (TGF-beta) and interleukin-6 (IL-6) in the generation of immunosuppressive macrophages (M phi s) in host spleen cells (...) of Mycobacterium avium complex (MAC)-infected mice was studied. M phi populations with potent suppressor activity against concanavalin A (Con A)-induced mitogenesis of splenocytes (SPCs) were elicited not only in euthymic but also in athymic nude mice during MAC infection. The suppressor M phi s are, therefore, inducible not only through a T-cell-dependent mechanism but also through T-cell-independent mechanism. However, MAC-induced M phi s of athymic mice displayed about four times lower suppressor activity

1996 Immunology PubMed abstract

1055. Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex. (Full text)

Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex. WR99210, a dihydrofolate reductase inhibitor, has promising in vitro activity against Mycobacterium avium complex (MAC). The in vitro activities of WR99210 alone and in combination with a fixed concentration of dapsone (0.5 microgram/ml) were evaluated against 35 clinical MAC isolates by a broth dilution method. The MIC at which 50% of isolates were inhibited (MIC50) and MIC90 of WR99210 alone

1996 Antimicrobial Agents and Chemotherapy PubMed abstract

1056. Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia (Full text)

Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia 12770995 2003 07 18 2018 11 13 0007-1161 87 6 2003 Jun The British journal of ophthalmology Br J Ophthalmol Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia. 798-9 Golchin B B McClellan K K eng Case Reports Letter England Br J Ophthalmol 0421041 0007-1161 0 Antibiotics, Antitubercular 1W306TDA6S Rifabutin IM AIDS-Related (...) Opportunistic Infections complications Antibiotics, Antitubercular adverse effects Bacteremia prevention & control Corneal Diseases chemically induced Endothelium, Corneal Humans Male Middle Aged Mycobacterium avium Complex Mycobacterium avium-intracellulare Infection complications prevention & control Rifabutin adverse effects 2003 5 29 5 0 2003 7 19 5 0 2003 5 29 5 0 ppublish 12770995 PMC1771698 N Engl J Med. 1993 Sep 16;329(12):828-33 8179648 Arch Ophthalmol. 1994 Sep;112(9):1159-65 8085960 Am J

2003 The British journal of ophthalmology PubMed abstract

1057. Intramacrophage Passage of Mycobacterium tuberculosis and M. avium Complex Alters the Drug Susceptibilities of the Organisms as Determined by Intracellular Susceptibility Testing Using Macrophages and Type II Alveolar Epithelial Cells (Full text)

Intramacrophage Passage of Mycobacterium tuberculosis and M. avium Complex Alters the Drug Susceptibilities of the Organisms as Determined by Intracellular Susceptibility Testing Using Macrophages and Type II Alveolar Epithelial Cells Mycobacterium tuberculosis and M. avium complex strains given intramacrophage passage (I-type) were compared with those cultured in a liquid medium (E-type) for their drug susceptibilities when they were replicating in Mono-Mac-6 macrophages or A-549 cells

2002 Antimicrobial Agents and Chemotherapy PubMed abstract

1058. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. (Full text)

Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. The therapeutic efficacy of liposomal clofazimine (L-CLF) against Mycobacterium avium complex (MAC) was evaluated in the acute and chronic infection models of the beige mouse (C57BL/6J bgj bgj). The maximum tolerated dose of L-CLF was inversely proportional to the infection level. L-CLF showed higher antibacterial activity than free clofazimine

1997 Antimicrobial Agents and Chemotherapy PubMed abstract

1059. Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice. (Full text)

Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice. Although various antimicrobial agents exhibit appreciable microbicidal activity in the early phase (weeks 2 t0 4) of Mycobacterium avium complex (MAC) infection induced in mice, progressive bacterial regrowth subsequently occurs. To clarify the reason for this pattern of changes, we studied changes in the levels of various cytokines in tissue at sites of infection

1997 Antimicrobial Agents and Chemotherapy PubMed abstract

1060. Comparison of CO2 Generation (BACTEC) and Viable-Count Methods To Determine the Postantibiotic Effect of Antimycobacterial Agents against Mycobacterium avium Complex (Full text)

Comparison of CO2 Generation (BACTEC) and Viable-Count Methods To Determine the Postantibiotic Effect of Antimycobacterial Agents against Mycobacterium avium Complex The postantibiotic effects (PAEs) of antimycobacterial agents determined with a BACTEC TB-460 instrument (CO2 production) and by a traditional viable-count method against Mycobacterium avium complex (MAC) were not significantly different (P > 0.05). The longest PAEs following a 2-h exposure to 2x the MIC were induced by amikacin

1998 Antimicrobial Agents and Chemotherapy PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>